New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
06:46 EDTOGXIOncoGenex downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded OncoGenex citing the failure of the SYNERGY trial. Price target lowered to $4.50 from $19.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
06:37 EDTOGXIOncoGenex completes patients enrolment for Rainier clinical trial
Subscribe for More Information
December 12, 2014
16:13 EDTOGXIBiotechnology Value Fund reports 6.43% passive stake in OncoGenex

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use